Diltiazem Drip Protocol for Atrial Fibrillation with Rapid Ventricular Response
Administer an initial IV bolus of diltiazem 0.25 mg/kg (approximately 15–20 mg for an average adult) over 2 minutes, followed by a continuous infusion starting at 5–10 mg/hour, titrating up to 15 mg/hour as needed to achieve a heart rate below 100–110 bpm. 1, 2
Initial Bolus Dosing
- Give 0.25 mg/kg actual body weight (typically 15–20 mg) as a slow IV push over 2 minutes. 1, 2
- If the heart rate remains above 100–110 bpm after 15 minutes and the patient tolerated the first dose without hypotension, administer a second bolus of 0.35 mg/kg (approximately 20–25 mg) over 2 minutes. 1, 2
- Maximal heart-rate reduction occurs within 2–7 minutes after bolus administration, with a median onset of 4.3 minutes. 1, 3
- The overall response rate (defined as >20% heart-rate reduction, conversion to sinus rhythm, or heart rate <100 bpm) is 93–94% after bolus dosing. 1, 3
Continuous Infusion Protocol
- Immediately after bolus administration and initial rate reduction, start a continuous infusion at 10 mg/hour. 2
- Some patients maintain adequate control at 5 mg/hour; this lower rate may be appropriate for elderly patients or those at risk of hypotension. 1, 2
- If rate control remains inadequate, titrate upward in 5 mg/hour increments (from 5 → 10 → 15 mg/hour) every 1–2 hours based on heart-rate response. 1, 2
- The maximum recommended infusion rate is 15 mg/hour, and infusions should not exceed 24 hours due to dose-dependent, non-linear pharmacokinetics. 2
- Target heart rate is <100 bpm (lenient control) or <80 bpm (strict control) at rest. 4, 1
Transition to Oral Therapy
- Once stable rate control is achieved on the infusion, transition to oral immediate-release diltiazem 30 mg, then maintain with 30–60 mg every 6–8 hours, titrating according to response. 1
- Oral immediate-release diltiazem may be as effective as continuous IV infusion after the initial loading dose, with a lower treatment-failure rate at 4 hours in one study. 5
Absolute Contraindications (Must Exclude Before Administration)
- Heart failure with reduced ejection fraction (HFrEF) or decompensated heart failure: Diltiazem's negative inotropic effect can precipitate hemodynamic collapse. 4, 1, 6
- Wolff-Parkinson-White syndrome or other pre-excitation syndromes: Diltiazem may accelerate ventricular response via the accessory pathway and precipitate ventricular fibrillation. 4, 1
- Wide-complex tachycardia or suspected ventricular tachycardia: Diltiazem is contraindicated when the rhythm suggests ventricular origin. 1
- Systolic blood pressure <90 mmHg: Hemodynamic instability precludes diltiazem use; immediate electrical cardioversion is required instead. 1, 3
- High-grade AV block (second- or third-degree block without a pacemaker) or sinus node dysfunction without a pacemaker. 1
Monitoring Requirements
- Continuously monitor heart rate and blood pressure during bolus and infusion; reassess every 15 minutes initially, then hourly once stable. 1
- Watch for hypotension (systolic BP <90 mmHg or symptomatic drops): hypotension occurs in 18–42% of patients, with 3.2% requiring intervention. 1, 7
- Monitor for excessive bradycardia (<50 bpm or symptomatic): elderly patients and those with paroxysmal atrial fibrillation have increased risk. 1
- If bradycardia or hypotension develops, reduce the infusion rate or discontinue diltiazem. 1
- Auscultate for signs of worsening heart failure (new pulmonary rales, peripheral edema), as diltiazem's negative inotropic effect can precipitate decompensation. 1
Dosing Considerations by Weight and Age
- Low body weight patients should be dosed strictly on a mg/kg basis rather than using fixed doses. 2
- Some patients may respond to an initial dose of 0.15 mg/kg, although duration of action may be shorter and experience with this dose is limited. 2
- Lower doses (<0.2 mg/kg) may be as effective as standard doses (0.2–0.3 mg/kg) while significantly reducing hypotension risk (18% vs. 35%, adjusted OR 0.39). 7
- Weight-based dosing (0.25 mg/kg) achieves rate control in 55% of patients by 30 minutes, compared to only 27% with low doses (<0.1875 mg/kg). 8
Alternative Agent: When to Use Beta-Blockers Instead
- Beta-blockers (metoprolol or esmolol) are preferred over diltiazem in patients with heart failure with reduced ejection fraction, as they provide mortality benefit. 4, 6
- For HFrEF patients, use the smallest dose of beta-blocker to achieve rate control; amiodarone is an option in hemodynamic instability or severely reduced LVEF. 4
- Esmolol (loading dose 500 mcg/kg over 1 minute, then 50–300 mcg/kg/min infusion) is favored for its rapid onset and short half-life, allowing immediate reversibility. 1
- Metoprolol (2.5–5 mg IV bolus over 2 minutes, repeated every 5 minutes up to 15 mg total) is equally appropriate for patients with preserved ejection fraction. 1
Common Pitfalls to Avoid
- Do not use diltiazem in patients with systolic heart failure or decompensated heart failure, even if they are hemodynamically stable at presentation; beta-blockers or digoxin are safer alternatives. 4, 1, 6
- Do not administer diltiazem in pre-excited atrial fibrillation (wide QRS with delta waves); this can be fatal. 4, 1
- Do not exceed 15 mg/hour infusion rate or continue beyond 24 hours, as safety and efficacy data are lacking for higher doses or longer durations. 2
- Do not give the full 25 mg second bolus if the patient developed hypotension after the first bolus; reassess hemodynamics before each dose. 1, 2
- Do not rely on diltiazem alone in patients with multifocal atrial tachycardia (MAT) associated with severe pulmonary disease; treat the underlying hypoxemia and acidosis first. 4